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AbstrAct
Objectives To seek evidence of the danger molecule, 
high-mobility group protein B1 (HMGB1) expression 
in human tendinopathy and thereafter, to explore 
mechanisms where HMGB1 may regulate inflammatory 
mediators and matrix regulation in human tendinopathy.
Methods Torn supraspinatus tendon (established 
pathology) and matched intact subscapularis tendon 
(representing ‘early pathology’) biopsies were collected 
from patients undergoing arthroscopic shoulder surgery. 
Control samples of subscapularis tendon were collected 
from patients undergoing arthroscopic stabilisation 
surgery. Markers of inflammation and HMGB1 were 
quantified by reverse transcriptase PCR (RT-PCR) and 
immunohistochemistry. Human tendon-derived primary 
cells were derived from hamstring tendon tissue obtained 
during hamstring tendon anterior cruciate ligament 
reconstruction and used through passage 3. In vitro 
effects of recombinant HMGB1 on tenocyte matrix and 
inflammatory potential were measured using quantitative 
RT-PCR, ELISA and immunohistochemistry staining.
Results Tendinopathic tissues demonstrated significantly 
increased levels of the danger molecule HMGB1 compared 
with control tissues with early tendinopathy tissue showing 
the greatest expression. The addition of recombinant 
human HMGB1 to tenocytes led to significant increase 
in expression of a number of inflammatory mediators, 
including interleukin 1 beta (IL-1β), IL-6, IL-33, CCL2 and 
CXCL12, in vitro. Further analysis demonstrated rhHMGB1 
treatment resulted in increased expression of genes 
involved in matrix remodelling. Significant increases were 
observed in Col3, Tenascin-C and Decorin. Moreover, 
blocking HMGB1 signalling via toll-like receptor 4 (TLR4) 
silencing reversed these key inflammatory and matrix 
changes.
Conclusion HMGB1 is present in human tendinopathy 
and can regulate inflammatory cytokines and matrix 
changes. We propose HMGB1 as a mediator driving the 
inflammatory/matrix crosstalk and manipulation of the 
HMGB1/TLR4 axis may offer novel therapeutic approaches 
targeting inflammatory mechanisms in the management of 
human tendon disorders.
IntroductIon
Overuse tendon injuries, namely tendinop-
athies, pose a significant, highly prevalent 
problem in rheumatological medicine with 
the diagnosis and management of shoulder 
tendon injuries alone amounting to an 
annual cost of $3 billion to the US health-
care system highlighting the huge burden 
of disease.1 The intrinsic pathogenetic 
mechanisms underlying the development 
of tendinopathies are largely unknown; 
however, inflammatory mechanisms have 
recently been implicated functionally in 
several model systems.2 Molecular evidence 
suggests that many of the key inflamma-
tory interactions occur in the early stages 
(acute/subacute) of repetitive tendon 
microtrauma when patients can be totally 
asymptomatic.3 At these early stages, 
changes in tissue microenvironments and 
crosstalk with the innate immune system 
interact at a crossroads between reparative 
versus degenerative ‘inflammatory’ healing. 
Additional evidence suggests that repeti-
tive biomechanical stress and its associated 
damage in stromal tissues play a key role in 
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Table 1 Patient details and demographics
Tear size Control Small (<1 cm2) Medium (>1–3 cm2) Large (>3–5 cm2)
Number of cases 6 4 2 2
Mean age in years (range) 21 (16–25) 48 (35–58) 50 (46–64) 52 (42–58)
Mean duration of symptoms in months (range) 4.0 (2–10) 7.8 (2–15) 6.3 (2–12) 9.8 (5–24)
Mean number of steroid injections 0 1.0 1.3 1.6
the immune systems response to regeneration.4 Thus, 
the pathological process of tendinopathy implicating 
repetitive microtrauma/stress and dysregulated matrix 
remodelling lends itself as a plausible alarmin-medi-
ated pathology.
Alarmins, also known as danger signals, are members 
of the damage-associated molecular group of proteins 
(DAMP) that are rapidly released into the extracellular 
compartment during tissue damage. High-mobility 
group protein B1 (HMGB1) is a widely expressed, 
highly conserved nuclear protein involved in transcrip-
tional regulation playing principal roles in a variety of 
inflammatory responses and diseases.5 HMGB1 acts 
as a DAMP after its release, which can occur passively 
from dead cells or actively by secretion from activated 
immune cells, and other cell types under stress.6 HMGB1 
signals through a family of receptors including receptor 
for advanced glycation endproducts (RAGE), toll-like 
receptor 2 (TLR2), TLR4, TLR9 and CD24-Siglec-10 
while also forming heterocomplexes with interleukin 1 
beta (IL-1ß), CXCL12 or lipopolysaccharide(LPS).7 8 
Importantly, stress conditions (hypoxia, mechanical) 
which are considered key to the onset and perpetuation 
of tendinopathy9 result in HMGB1 release. Extracellular 
HMGB1 induces several responses, including the elabo-
ration of proinflammatory cytokines, cell proliferation 
and stromal cell matrix responses.10 Emerging evidence 
indicates that HMGB1 contributes to many diseases 
with dysregulated matrix responses such as rheumatoid 
arthritis (RA), liver fibrosis and progressive pulmonary 
fibrosis11 and HMGB1 binding and signalling through 
TLR4 mediate cytokine tissue injury. Moreover, agents 
targeting HMGB1 have delivered promising in vitro and 
in vivo data12 particularly altering matrix regulation, 
suggesting that HMGB1 may offer therapeutic utility.
One of the major limitations of human studies is that 
tendon biopsies are usually obtained when patients are 
symptomatic and therefore biopsy material is likely to 
represent chronic, rather than early phase processes. We 
previously suggested that matched subscapularis tendon 
from patients with full thickness rotator cuff tears may 
be a model of early human tendinopathy based on histo-
logical appearances and significantly increased levels of 
cytokines and apoptotic markers in these tissues.13 The 
purpose of this study was to formally assess the expression 
of HMGB1 within this human model of tendinopathy and 
thereafter explore the mechanistic activities of HMBG1 
on inflammation and matrix production in tenocytes in 
vitro.
Methods
Human model of tendinopathy
All procedures and protocols were approved by the 
Ethics Committee under approval number No. 99/101 
with informed consent obtained and carried out in 
accordance with standard operative procedures. Eight 
supraspinatus tendon samples were collected from 
patients with rotator cuff tears undergoing shoulder 
surgery. The mean age of the rotator cuff ruptured 
patients was 50 years (range, 35–64 years) (table 1)—the 
mean tear size was 2.4 cm2 (range 1–5 cm2). Samples of 
the subscapularis tendon were also collected from the 
same patients. Patients were only included if there was no 
clinically detectable evidence of subscapularis tendinop-
athy on a preoperative MRI scan or macroscopic damage 
to the subscapularis tendon at the time of arthroscopy—
by these criteria they represented a preclinical cohort. 
In this cohort, all patients fulfilled the following criteria: 
(1) a history of shoulder pain and dysfunction, (2) no 
previous surgery on the affected shoulder, (3) no radio-
graphic sign of fracture of the shoulder and (4) no 
history of RA or osteoarthritis (OA). An independent 
control group was obtained comprising six samples of 
subscapularis tendon collected from patients undergoing 
arthroscopic surgery for shoulder stabilisation without 
rotator cuff tears, no previous shoulder surgery, no radio-
graphic signs of shoulder fracture, or history of RA or 
OA. The absence of rotator cuff tears was confirmed by 
arthroscopic examination. The mean age of the control 
group was 21 years (range, 16–25 years). Additionally, 
standardised patient demographics14 were obtained 
preoperatively and included the duration of shoulder 
symptoms experienced by the patient and the number of 
subacromial steroid injections (table 1).
tissue collection and preparation
Arthroscopic repair of the rotator cuff was carried out 
using the standard three-portal technique while the 
cross-sectional size of the rotator cuff tear was estimated 
and recorded as previously described.15 The subscapularis 
tendon was biopsied arthroscopically from the superior 
border of the tendon 1 cm lateral to the glenoid labrum 
representing mid-body tendon structure. The supraspi-
natus tendon was harvested from within 1.5 cm of the 
edge of the tear prior to surgical repair. For immunohis-
tochemical staining the tissue samples were immediately 
fixed in 10% (v/v) formalin for 4–6 hours and then 
embedded in paraffin. Sections were cut to 5 µm thick-
ness using a Leica-LM microtome (Leica Microsystems, 
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Germany) and placed onto Superfrost Ultra Plus glass 
slides (Gerhard Menzel, Germany). The paraffin was 
removed from the tissue sections with xylene, rehydrated 
in graded alcohol and used for histological and immu-
nohistochemical staining per previously established 
methodologies.16
cell culture and treatments
Human tendon-derived cells were explanted from 
hamstring tendon tissue of five patients (aged 18–30 
years, mean 22 years) undergoing hamstring tendon 
anterior cruciate ligament reconstruction. Cultures were 
maintained in RPMI supplemented with 10% fetal calf 
serum, 100 U/mL penicillin, 100 µg/mL streptomycin 
(all Gibco, Scotland, UK), at 37°C in a humidified atmo-
sphere of 5% CO2 for 28 days. Cells were subcultured and 
trypsinised at subconfluency, with cells from the second 
and third passages used.
Cells were plated at 25 000 cells/well in a 12-well 
plate and allowed to rest for 48 hours in a tissue culture 
incubator at 37°C with 5% CO2 content. The culture 
medium was discarded and the cells treated as required 
with the relevant recombinant proteins. The cells were 
incubated for 24 hours with disulfide rhHMGB1 (Tecan, 
Switzerland), LPS (Sigma Aldrich, Cambridge, UK) 
or IL-1β (Biolegend, London, UK) at concentrations 
as described in the figure legends. Levels of HMGB1 
protein following stimulation of explanted healthy teno-
cytes with LPS (1 ng/mL) and IL-1ß (1 ng/mL) were 
measured by ELISA (Novus Biologicals). Furthermore, 
human tendon-derived cells were explanted from our 
patient cohort with early tendinopathy (six patients) and 
placed into chamber slides and stained for HMGB1 and 
TLR4 expression as described in the histology/immuno-
histochemistry techniques.
histology and immunohistochemistry techniques
Samples were stained with H&E and toluidine blue for 
determination of the degree of tendinopathy as assessed 
by a modified version of the Bonar score17 (Grade 
4=marked tendinopathy, Grade 3=advanced tendinop-
athy, Grade 2=moderate degeneration, Grade 1=mild 
degeneration, Grade 0=normal tendon). This included 
the presence or absence of oedema and degeneration 
together with the degree of fibroblast cellularity and chon-
droid metaplasia. Thereafter, sections were stained with a 
range of primary monoclonal antibodies directed against 
the following markers: HMGB1 (Cambridge Biosci-
ence, UK; 2.5 µg/mL, 1:200 dilution), CD45 (Biolegend; 
5 µg/mL, 1:100 dilution) and TLR4 (Lifespan Biosci-
ences, Seattle, USA; 1 mg/mL, 1:100 dilution).
Endogenous peroxidase activity was quenched with 3% 
(v/v) H2O2, and non-specific antibody binding blocked 
with 2.5% horse serum in Tris buffered saline (TBS) solu-
tion with detergent Tween20 (TBST) buffer for 30 min. 
Antigen retrieval was performed in 0.01 M citrate buffer 
for 20 min in a microwave. Sections were incubated with 
primary antibody in 2.5% (w/v) horse serum/human 
serum/TBST at 4°C overnight. After two washes, slides 
were incubated with Vector ImmPRESS Reagent kit as 
per manufacturer’s instructions for 30 min. The slides 
were washed and incubated with Vector ImmPACT DAB 
chromagen solution for 2 min, followed by extensive 
washing. Finally, the sections were counterstained with 
haematoxylin.
Images were captured using Apple Open laboratory 
software. Positive (human tonsil tissue) control specimens 
were included, in addition to the surgical specimens for 
each individual antibody staining technique and double 
immunofluorescence staining. Omission of primary anti-
body and use of negative control (human OA samples) 
isotypes confirmed the specificity of staining.
We applied a scoring system based on previous 
methods18 to quantify the immunohistochemical staining. 
Five random high-power fields (×400) were evaluated by 
two independent assessors (NLM, JHR). In each field, 
the number of positive and negatively stained cells were 
counted and the percentage of positive cells calculated 
giving the following semiquantitative grading: Grade 
0=no staining, Grade 1=<10% cells stained positive, 
Grade2=10%–20% cells stained positive, Grade 3=>20% 
cells positive. Additional subanalysis of HMGB1-positive 
cells calculated the actual number of double-stained cells 
per high-power field.
rnA extraction and quantitative Pcr
Tissue from 14 patients was available for RNA analysis and 
was placed in RNALater (Ambion) at the time of surgery. 
mRNA from cells harvested from in vitro experiments, 
along with the available biopsy samples, was extracted 
as per PureLink RNA Mini Kit (Thermo Fisher, Paisley, 
UK) instructions. cDNA was prepared from RNA samples 
using the High Capacity cDNA Reverse Transcription 
Kit (Thermo Fisher) as per manufacturer’s instructions. 
SYBR green real-time PCR was performed using PowerUp 
SYBR Green Master Mix (Thermo Fisher). Prior to setting 
up the SYBR green the cDNA was diluted 1 in 5 using 
RNase-free water. Each sample was analysed in triplicate. 
Primers (Integrated DNA Technologies, Belgium) were 
as follows: 18 s, 5′-GTA ACC CGT TGA ACC CCA TT-3′ 
(F) and 5′-CCA TCC AAT CGG TAG TAG CG-3′ (R), 
GAPDH, 5′-TCG ACA GTC AGC CGC ATC TTC TTT-3′ 
(F) and 5′-ACC AAA TCC GTT GAC TCC GAC CTT-3′ 
(R), Tenascin C, 5′-GTG CCA GGA GAC CGT ACC AC-3′ 
(F) and 5′-CTT TGG CTG GGT TGC TTG AC-3′ (R), 
Decorin, 5′-CGC CTC ATC TGA GGG AGC TT-3′ (F) and 
5′-TAC TGG ACC GGG TTG CTG AA-3′ (R), COL1A, 
5′-CAA TGC TGC CCT TTC TGC TCC TTT-3′ (F) and 
5′-CAC TTG GGT GTT TGA GCA TTG CCT-3′ (R), COL 
3A, 5′-TAT CGA ACA CGC AAG GCT GTG AGA-3′ (F) 
and 5′-GGC CAA CGT CCA CAC CAA ATT CTT-3′ (R), 
Periostin, 5′-TTG AGA CGC TGG AAG GAA AT-3′ (F) 
and 5′-AGA TCC GTG AAG GTG GTT TG-3′ (R), IL-1β, 
5′-CAC CTG TAC GAT CAC TGA ACT G (F) and 5′-AAC 
ACC ACT TGT TGC TCC ATA-3′ (R), CCL2, 5′-CTC AGC 
CAG ATG CAA TCA ATG (F) and 5′-TGC TGC TGG TGA 
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TTC TTC TAT-3′ (R), TGF β1, 5′-CTA ATG GTG GAA 
ACC CAC AAC G (F) and 5′-TAT CGC CAG GAA TTG 
TTG CTG-3′ (R), IL-33, 5′-GGA AGA ACA CAG CAA 
GCA AAG CCT-3′ (F) and 5′-AA GGC CAG AGC GGA 
GCT TCA TAA-3′ (R), CXCL12, 5′-CAT GCC GAT TCT 
TCG AAA GC-3′ (F) and 5′-TTC AGC CGG GCT ACA 
ATC-3′ (R), IL-6, 5′-CAC TCA CCT CTT CAG AAC GAA 
T-3′ (F) and 5′-GCT GCT TTC ACA CAT GTT ACT C-3′ 
(R), siRNA experiments.
Following 48 hours of cell attachment, as described 
above, the cells were transfected with a validated prede-
signed TLR4 siRNA or non-specific control siRNA for 
48 hours using Lipofectamine 2000 (Thermo Fisher) 
according to the manufacturer’s instructions. Forty-
eight hours after transfection, the cells were transfected 
again for an additional 24 hours. Following this, the 
transfection medium was then replaced and cells treated 
with rhHMGB1 as described previously.
statistical analysis
Results are reported as mean values ± SEM. Analysis of 
variance (ANOVA) followed by Tukey’s test, Student’s 
t-test or Mann-Whitney U test was applied to in vitro 
studies. Analysis between individual in vitro groups was 
examined by ANOVA followed by the Student-Newman-
Keuls test using GraphPad Prism, V.6.0 (GraphPad, CA). 
Correlations utilising patient metadata were calculated 
with use of the Pearson coefficient. A value of p<0.05 was 
considered to be significant.
results
Early tendinopathy shows increased HMGb1 expression
HMGB1 message (figure 1A) and protein (figure 1B,C) 
were significantly upregulated in early tendinopathy 
samples compared with control and torn tendon samples. 
There were no significant correlations between HMGB1 
expression and the mean duration of symptoms, patient 
age or number of steroid injections. HMGB1 was mainly 
expressed by stromal cells in the extracellular matrix 
(figure 1D). Furthermore, to verify the main HMGB1 
expressing cell type, immunofluorescence staining with 
CD45 (pan immune cell marker) revealed <5% cells to 
be of immune cell lineage confirming within human 
biopsies (n=6) that the majority of HMGB1 expression 
are within the stromal compartment (figure 1E). Human 
tendon biopsies were explanted and demonstrated 
40%–60% of tenocytes were positive for HMGB1 protein 
with coexisting TLR4 receptor expression (figure 1F). 
Furthermore, HMGB1 release was induced by TLR4 
agonism via LPS stimulation and inflammatory activation 
via IL-1β stimulation (figure 1G) as measured by ELISA.
Late tendinopathy samples exhibited marked degener-
ation, mucoid change and frank chondroid metaplasia 
(grade 4), whereas matched subscapularis tendon 
biopsies had grade 2–3 changes indicative of early tend-
inopathy. All control samples were classified as grade 1 
consistent with normal fibrotendinous tissue with large 
distinct collagen fibrils.
hMGB1 promotes a proinflammatory tendon phenotype in 
vitro
We next explored the extent to which HMGB1 could 
regulate the local inflammatory milieu via modulating 
tenocyte behaviour. The absence of RAGE, TLR 2 and 
9 (data not shown, underdetermined Ct on reverse tran-
scriptase-PCR), but the presence of TLR 4 mRNA by 
quantitative real-time PCR was confirmed in cultured 
human tenocytes. The addition of recombinant human 
HMGB1 led to significant increase in expression of a 
number of inflammatory mediators, including IL-1β, 
IL-6, IL-33, CCL2 and CXCL12, suggesting a resultant 
proinflammatory phenotype (figure 2A).
hMGB1 promotes dysregulated matrix in tenocytes
Since dysregulated matrix remodelling is a feature of 
tendinopathy, we next considered whether HMGB1 might 
alter differential matrix synthesis in vitro. rhHMGB1 
(using dose/time points optimisation derived in prelim-
inary experiments) significantly elevated Collagen 3A, 
Tenascin-C and Decorin mRNA at 24 compared with 
controls (figure 2B). No effect was seen on Collagen 1 or 
Periostin mRNA with rhHMGB1 treatment.
targeting tlr4 reduces hMGB1-induced inflammatory/
matrix changes in tenocytes in vitro
Finally, we wished to explore whether inhibiting the 
signalling capacity of HMGB1 would reduce the proin-
flammatory phenotype of tenocytes in vitro. TLR4 siRNA 
significantly reduced the HMGB1-induced proinflam-
matory cytokine/chemokine production of IL-1β, IL-6, 
IL-33, CCL2 and CXCL12 (figure 3). Furthermore, TLR4 
knock-down was able to reverse the aberrant matrix gene 
production of Collagen 3, Tenascin-C and Decorin.
dIscussIon
Our study provides evidence that HMGB1 could operate 
as a damage-associated modulator of early tendinopathy. 
Herein we demonstrate that HMGB1 is present in early 
tendinopathy biopsies and thereafter in mechanistic 
studies demonstrate that HMGB1 likely contributes 
to regulation of inflammatory and matrix pathways in 
tendon cells via TLR4 signalling (figure 4).
HMGB1 acts as a DAMP after its release upon stress 
conditions and further induces proinflammatory 
cytokines, cell proliferation and stromal cell matrix 
responses, thus contributing to damage-associated 
musculoskeletal pathologies.11 A recent study in four 
patients with glenohumeral arthritis revealed increased 
HMGB1 expression in biceps tendon samples,19 
suggesting an inflammatory environment may drive 
upregulation of HMGB1 protein within tenocytes. 
We previously identified DAMPs that are significantly 
altered in damaged human and murine tendons.20 In 
the context of tendinopathy, our data suggest HMGB1 is 
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Figure 1 HMGB1 expression in human tendinopathy samples. (A) HMGB1 gene expression in tendon samples. Delta 
Ct values of HMGB1 in control (n=6, intact subscapularis biopsy), late tendinopathy (torn supraspinatus biopsy, n=8) and 
early tendinopathy (matched intact subscapularis biopsy, n=8) human tendon samples. Data are mean ± SEM relative to 
housekeeping gene GAPDH (mean of duplicate analysis). *p<0.05, **p<0.01 (ANOVA) relative to control biopsies. (B) Control, 
late tendinopathy and early human tendinopathy sample stained for HMGB1, isotype IgG in bottom right corner using rabbit 
polyclonal HMGB1 antibody at ×10 and ×40 magnification. (C) Graphs illustrate modified Bonar scoring for samples of 
human tendon biopsies for expression of HMGB1 with mean and SEM shown. n=8 for control tendon, n=10 for early and 
late tendinopathy. Modified Bonar scoring system depicts mean score per sample based on five high-power fields. 0= no 
staining, 1=<10%, 2=10%–20%, 3=>20% positive staining of cells per high-power field. *p<0.05, **p<0.01 (ANOVA) versus 
control biopsies. #p<0.05 late versus early tendinopathy. (D) Double immunofluorescence staining using rabbit polyclonal 
HMGB1 antibody showing HMGB1, CD45 (pan immune cell) double staining colocalisation in early tendinopathy sample 
(×100). (E) Quantitative expression of HMGB1+ and CD45+/HMGB1+ depicts mean cells per sample based on 10 high-power 
fields. n=6 for control tendon, late and early tendinopathy. (F) HMGB1 and TLR4 staining in explanted early tendinopathy 
human biopsies at ×10 and ×40 magnification. (G) ELISA for HMGB1 protein release (ng/mL) in supernatants from control (no 
treatment), 1 ng/mL LPS and 1 ng/mL IL-1ß treated explanted ACL human tenocytes. **p<0.01 vs 0 control, #p<0.05 versus 
LPS control (Mann-Whitney U test). ACL, anterior cruciate ligament; ANOVA, analysis of variance; GAPDH, glyceraldehyde 
3-phosphate dehydrogenase; HMGB1, high-mobility group protein B1; HPF, high-power fields; IL-1β, interleukin 1 beta, LPS 
lipopolyscacharide.
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Figure 2 HMGB1 drives a proinflammatory and matrix remodelling phenotype in tenocytes in vitro. (A) The levels of mRNA 
for IL-1β, CCl-2, IL-33, CXCL-12, IL-6 and TGF-β and (B) Tenascin C, Decorin, Collagen 1, Collagen 3 and Periostin were 
determined by real-time PCR over a 24-hour time (4 µg/mL rhHMGB1, 1 ng/mL LPS). Data are shown as the mean ± SEM 
of triplicate samples and represent experiments on five individual normal hamstring tendon patient explant samples utilising 
GAPDH housekeeping. *p<0.05, **p<0.01 (ANOVA) versus control or versus LPS control above. ANOVA, analysis of variance; 
GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HMGB1, high-mobility group protein B1; IL-1β, interleukin 1 beta; 
TGF-β, transforming growth factor beta, LPS, lipopolysaccharide.
dysregulated in early disease and when released into the 
extracellular matrix promotes the production of proin-
flammatory cytokines IL-1β, IL-6 and IL-33. In particular, 
the IL-1 superfamily (IL-1β and IL-33) is known as 
potent mediators in driving aberrant matrix remod-
elling in human tenocytes linking inflammation and 
extracellular matrix(ECM) remodelling.21 22 Further-
more, our data revealed that HMGB1 acted on tenocytes 
in vitro to enhance the production of the chemokines 
CCL2 and CXCL12 which have been implicated in 
RA synovitis23 and are produced by OA synovium24 in the 
presence of proinflammatory cytokines. They are also 
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Figure 3 The effect of TLR4 blockade on HMGB1 induced changes in tenocytes in vitro. The levels of mRNA for TLR4, IL-1β, 
CCl-2, IL-33, CXCL-12, IL-6 and TGF-β and Tenascin C, Decorin, Collagen 1 and Collagen 3 were determined by real-time PCR 
following transfection with a validated predesigned TLR4 siRNA or non-specific control siRNA for 48 hours using Lipofectamine 
2000. Data are shown as the mean ± SEM of triplicate samples and represent experiments on five individual normal hamstring 
tendon patient explant samples utilising 18S housekeeping versus control. *p<0.05, **p<0.01 versus control (ANOVA). ANOVA, 
analysis of variance; HMGB1, high-mobility group protein B1; IL-1β, interleukin 1 beta; TGF-β, transforming growth factor beta.
involved in the induction of macrophage and fibroblast 
chemotaxis in musculoskeletal diseases25 advocating a 
role for HMGB1 in immune/stromal cell interactions 
in tendon. Additionally, evidence suggests that HMGB1 
can act synergistically in the presence of CXCL-1226 by 
forming hetereocomplexes which may explain HMGB1 
induces such a potent inflammatory response in teno-
cytes in vitro. Taken together, the enhanced production 
of these mediators in the presence of HMGB1 supports 
a role for this protein in the amplification of the inflam-
matory response of human tendon disease.
Resident stromal cells contribute significantly to 
tissue homeostasis associated with chronic inflammatory 
diseases such as RA/OA.27 Emerging evidence points 
to an intriguing scenario where stromal cell functions 
extend beyond maintenance of tissue architecture to 
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Figure 4 The role of HMGB1/TLR4 in tendon disease. Schematic diagram illustrating the manner in which early tendinopathy 
may arise due tenocyte HMGB1 expression/release. An increased stress that a tendon cell experiences results in the release 
of HMGB1 from tenocytes, which interacts to drive a proinflammatory phenotype with aberrant tendon remodelling towards an 
early tendinopathic process. HMGB1, high-mobility group protein B1; IL, interleukin.
include a key role in choreographing immune responses 
and thereby defining disease persistence. We have 
proposed the resident tenocyte as the central stromal 
regulator reacting to damage with DAMP upregulation 
and resultant matrix crosstalk3 and recent evidence points 
to tenocyte stromal activation in disease.28 Herein, the 
majority of HMGB1-expressing cells are tenocytes/resi-
dent stroma with <5% representing influxing/resident 
immune cells suggesting tenocytes as the main source 
of HMGB1 within the stromal compartment. Levels of 
HMGB1 are upregulated in the synoviocytes and fibro-
blasts in response to injury or inflammatory stimuli.29 
Furthermore, blockade of TLR4 signalling is able to 
partially reverse the proinflammatory tenocyte pheno-
type in vitro raising the possibility of TLR4 blockade as 
a therapeutic entity in human tendon disease. Further 
investigation is now required to understand the signalling 
biology of HMGB1 on matrix homeostasis, particularly as 
Decorin may be considered a reparative matrix protein30 
and thus fully appreciate optimal translational targets.
There are limitations inherent in our study. Age-related 
changes within the tendon samples could contribute 
to the degenerative picture and inflammatory cell 
expression seen in the matched subscapularis tendons. 
However, the lack of degenerative changes on MRI and 
arthroscopic examinations suggests that the differences 
are truly at the cellular level as suggested by our previous 
work.13 Subscapularis tendon is functionally and organi-
sationally distinct from supraspinatus and thus responds 
to mechanical loading in a different manner that may 
alter its cellular profile. Control samples from subscapu-
laris undergoing stabilisation may not be truly ‘normal’ 
controls but are currently the best available control 
tendon sample and this is reflected by a Bonar score 
of 1. It is reassuring however that we found the same 
inflammatory cell subtypes in matched subscapularis 
tissue indicating that the inflammatory response may be 
uniform within joints subjected to tendon degeneration. 
In addition, having subscapularis samples from the same 
patient eliminates bias that may result from variation 
between individuals and has been previously shown to be 
a useful method in sampling of tissues.31 We point out 
also that while our human tissue biopsies show presence 
of HMGB1 at mRNA and protein levels, the majority 
of our mechanistic work use an in vitro culture system 
and that further mechanistic investigation in an in vivo 
tendon model and late disease in vitro cultures may more 
likely address the hierarchal role of HMGB1 in tendon 
remodelling.
conclusIon
On the basis of these results we propose HMGB1 as an 
inflammatory regulator and influential damage sensing 
molecule in tendon remodelling - better understanding 
of the pathological cascade that it induces should lead 
to the development of cell targeted treatment modalities 
for early human tendinopathy.
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